CSS
RARE icon

Cubist Systematic Strategies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cubist Systematic Strategies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.19M Buy
172,674
+87,392
+102% +$2.62M 0.02% 942
2025
Q2 		$3.1M Sell
85,282
-36,228
-30% -$1.31M 0.01% 1312
2025
Q1 		$4.4M Buy
+121,510
New +$5.05M 0.03% 961
2024
Q4 		– Sell
-183,490
Closed -$10.2M – 3460
2024
Q3 		$10.2M Buy
+183,490
New +$9.35M 0.06% 443
2024
Q2 		– Sell
-22,631
Closed -$1.06M – 3828
2024
Q1 		$1.06M Buy
+22,631
New +$1.07M 0.01% 2128
2023
Q4 		– Sell
-29,178
Closed -$1.04M – 4007
2023
Q3 		$1.04M Sell
29,178
-133,156
-82% -$5.28M 0.01% 1859
2023
Q2 		$7.49M Sell
162,334
-70,634
-30% -$3.28M 0.05% 600
2023
Q1 		$9.34M Buy
232,968
+7,769
+3% +$333K 0.06% 496
2022
Q4 		$10.4M Sell
225,199
-19,380
-8% -$762K 0.06% 453
2022
Q3 		$10.1M Buy
244,579
+231,245
+1,734% +$11.9M 0.06% 472
2022
Q2 		$796K Sell
13,334
-26,819
-67% -$1.65M ﹤0.01% 2659
2022
Q1 		$2.92M Buy
40,153
+32,913
+455% +$2.29M 0.02% 1175
2021
Q4 		$609K Sell
7,240
-32,208
-82% -$2.62M 0.01% 2305
2021
Q3 		$3.56M Sell
39,448
-143,360
-78% -$13M 0.04% 652
2021
Q2 		$17.4M Buy
182,808
+148,274
+429% +$15.4M 0.2% 78
2021
Q1 		$3.93M Sell
34,534
-38,715
-53% -$5.27M 0.05% 571
2020
Q4 		$10.1M Buy
73,249
+39,317
+116% +$4.66M 0.14% 155
2020
Q3 		$2.79M Buy
+33,932
New +$2.81M 0.04% 705
2020
Q2 		– Sell
-10,863
Closed -$483K – 2506
2020
Q1 		$483K Sell
10,863
-9,093
-46% -$472K 0.01% 1276
2019
Q4 		$852K Sell
19,956
-17,346
-47% -$716K 0.02% 1261
2019
Q3 		$1.6M Buy
37,302
+34,396
+1,184% +$1.87M 0.03% 735
2019
Q2 		$185K Buy
+2,906
New +$185K ﹤0.01% 2074
2019
Q1 		– Sell
-19,929
Closed -$867K – 2391
2018
Q4 		$867K Buy
19,929
+11,709
+142% +$640K 0.04% 633
2018
Q3 		$628K Buy
+8,220
New +$669K 0.03% 697
2018
Q2 		– Sell
-2,592
Closed -$132K – 1996
2018
Q1 		$132K Sell
2,592
-3,185
-55% -$160K 0.01% 1538
2017
Q4 		$268K Sell
5,777
-3,510
-38% -$172K 0.01% 1332
2017
Q3 		$495K Buy
9,287
+3,717
+67% +$220K 0.03% 837
2017
Q2 		$346K Buy
5,570
+2,538
+84% +$153K 0.02% 948
2017
Q1 		$206K Buy
+3,032
New +$231K 0.01% 1166
2016
Q2 		– Sell
-6,921
Closed -$438K – 1847
2016
Q1 		$438K Buy
6,921
+3,472
+101% +$227K 0.03% 815
2015
Q4 		$387K Sell
3,449
-8,851
-72% -$885K 0.02% 962
2015
Q3 		$1.19M Buy
+12,300
New +$1.41M 0.06% 477
2015
Q2 		– Sell
-14,808
Closed -$919K – 2004
2015
Q1 		$919K Buy
14,808
+4,356
+42% +$242K 0.05% 618
2014
Q4 		$459K Buy
+10,452
New +$479K 0.02% 916

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Cubist Systematic Strategies's RARE Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Ultragenyx Pharmaceutical (RARE) stake by 102% in Q3 2025, buying an estimated $2.62M and bringing the position to 172,674 shares worth $5.19M. The position accounts for 0.02% of the portfolio, ranked #942.

Cubist Systematic Strategies first reported a position in RARE in Q4 2014 and has held it in 34 quarters since. The position peaked at $17.4M in Q2 2021. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Cubist Systematic Strategies held 172,674 shares of Ultragenyx Pharmaceutical worth $5.19M as of Q3 2025.
  • Cubist Systematic Strategies bought 87,392 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $2.62M.
  • Ultragenyx Pharmaceutical made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #942 holding.
  • Cubist Systematic Strategies first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 34 quarters since.
  • Cubist Systematic Strategies's Ultragenyx Pharmaceutical position peaked at $17.4M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.